Management of Important Adverse Events Associated with Inotuzumab Ozogamicin: Expert Panel Review

Overview

Journal Bone Marrow Transplant

Specialty General Surgery

Date 2018 Jan 14

PMID 29330398

Citations 54

Authors

Partow Kebriaei

Corey Cutler

Marcos de Lima

Sergio Giralt

Stephanie J Lee

David Marks

Akil Merchant

Wendy Stock

Koen Van Besien

Matthias Stelljes

Affiliations

Soon will be listed here.

Citing Articles

Antibody-Based Immunotherapies for the Treatment of Hematologic Malignancies.

Jureczek J, Kalwak K, Dziegiel P Cancers (Basel). 2025; 16(24.

PMID: 39766080 PMC: 11674729. DOI: 10.3390/cancers16244181.

Ph- ALL: immunotherapy in upfront treatment.

Stelljes M Hematology Am Soc Hematol Educ Program. 2024; 2024(1):86-92.

PMID: 39644077 PMC: 11665523. DOI: 10.1182/hematology.2024000531.

Transplant in ALL: who, when, and how?.

Marcoux C, Kebriaei P Hematology Am Soc Hematol Educ Program. 2024; 2024(1):93-101.

PMID: 39644076 PMC: 11665609. DOI: 10.1182/hematology.2024000533.

Ocular adverse events associated with antibody-drug conjugates in oncology: a pharmacovigilance study based on FDA adverse event reporting system (FAERS).

Mao K, Chen P, Sun H, Zhong S, Zheng H, Xu L Front Pharmacol. 2024; 15:1425617.

PMID: 39228525 PMC: 11368736. DOI: 10.3389/fphar.2024.1425617.

Liver elastography for risk-assessment of liver toxicity and risk factors for Sinusoidal obstruction syndrome in patients with acute lymphoblastic leukemia receiving inotuzumab ozogamicin.

Senapati J, Jabbour E, Short N, Jain N, Haddad F, Bathala T Blood Cancer J. 2024; 14(1):129.

PMID: 39112504 PMC: 11306742. DOI: 10.1038/s41408-024-01098-4.

References

Freifeld A, Bow E, Sepkowitz K, Boeckh M, Ito J, Mullen C . Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2011; 52(4):e56-93. DOI: 10.1093/cid/cir073. View

Coiffier B, Altman A, Pui C, Younes A, Cairo M . Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol. 2008; 26(16):2767-78. DOI: 10.1200/JCO.2007.15.0177. View

Carreras E . How I manage sinusoidal obstruction syndrome after haematopoietic cell transplantation. Br J Haematol. 2014; 168(4):481-91. DOI: 10.1111/bjh.13215. View

Lenz H . Management and preparedness for infusion and hypersensitivity reactions. Oncologist. 2007; 12(5):601-9. DOI: 10.1634/theoncologist.12-5-601. View

Kantarjian H, DeAngelo D, Advani A, Stelljes M, Kebriaei P, Cassaday R . Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study. Lancet Haematol. 2017; 4(8):e387-e398. DOI: 10.1016/S2352-3026(17)30103-5. View

Mohty M, Malard F, Abecassis M, Aerts E, Alaskar A, Aljurf M . Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2016; 51(7):906-12. PMC: 4935979. DOI: 10.1038/bmt.2016.130. View

Kantarjian H, DeAngelo D, Stelljes M, Martinelli G, Liedtke M, Stock W . Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. N Engl J Med. 2016; 375(8):740-53. PMC: 5594743. DOI: 10.1056/NEJMoa1509277. View

Avvisati G, Tirindelli M, Annibali O . Thrombocytopenia and hemorrhagic risk in cancer patients. Crit Rev Oncol Hematol. 2003; 48(Suppl):S13-6. DOI: 10.1016/j.critrevonc.2003.04.001. View

Mohty M, Malard F, Abecassis M, Aerts E, Alaskar A, Aljurf M . Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2015; 50(6):781-9. PMC: 4456788. DOI: 10.1038/bmt.2015.52. View

10.

Gauer R, Braun M . Thrombocytopenia. Am Fam Physician. 2012; 85(6):612-22. View

11.

Coppell J, Richardson P, Soiffer R, Martin P, Kernan N, Chen A . Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transplant. 2009; 16(2):157-68. PMC: 3018714. DOI: 10.1016/j.bbmt.2009.08.024. View

12.

Mehta H, Malandra M, Corey S . G-CSF and GM-CSF in Neutropenia. J Immunol. 2015; 195(4):1341-9. PMC: 4741374. DOI: 10.4049/jimmunol.1500861. View

13.

Rajvanshi P, Shulman H, Sievers E, McDonald G . Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. Blood. 2002; 99(7):2310-4. DOI: 10.1182/blood.v99.7.2310. View

14.

Gokbuget N, Stanze D, Beck J, Diedrich H, Horst H, Huttmann A . Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood. 2012; 120(10):2032-41. DOI: 10.1182/blood-2011-12-399287. View

15.

Shor B, Gerber H, Sapra P . Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies. Mol Immunol. 2014; 67(2 Pt A):107-16. DOI: 10.1016/j.molimm.2014.09.014. View

16.

Mirrakhimov A, Voore P, Khan M, Ali A . Tumor lysis syndrome: A clinical review. World J Crit Care Med. 2015; 4(2):130-8. PMC: 4411564. DOI: 10.5492/wjccm.v4.i2.130. View

17.

Curigliano G, Spitaleri G, de Braud F, Cardinale D, Cipolla C, Civelli M . QTc prolongation assessment in anticancer drug development: clinical and methodological issues. Ecancermedicalscience. 2012; 3:130. PMC: 3223992. DOI: 10.3332/ecancer.2009.130. View

18.

Dalle J, Giralt S . Hepatic Veno-Occlusive Disease after Hematopoietic Stem Cell Transplantation: Risk Factors and Stratification, Prophylaxis, and Treatment. Biol Blood Marrow Transplant. 2015; 22(3):400-9. DOI: 10.1016/j.bbmt.2015.09.024. View

19.

Shulman H, Fisher L, Schoch H, Henne K, McDonald G . Veno-occlusive disease of the liver after marrow transplantation: histological correlates of clinical signs and symptoms. Hepatology. 1994; 19(5):1171-81. View

20.

Crawford J, Dale D, Lyman G . Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer. 2004; 100(2):228-37. DOI: 10.1002/cncr.11882. View